K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice

Yi Hong Zhang, Dushyant Mann, James Raymick, Sumit Sarkar, Merle G. Paule, Debomoy Lahiri, Melanie Dumas, Ashlee Bell-Cohen, Larry C. Schmued

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common age related human neurodegenerative disorder. The major histopathological characteristics of the AD brain are extracellular amyloid-beta (Aβ) peptide loaded plaques and intraneuronal neurofibrillary tangles made of phosphorylated tau proteins. Amyloid plaques consist primarily of aggregated Aβ1-42 and Aβ1-40 peptides. The aim of our current study was to test novel ligands/agents with the potential to disrupt or inhibit the aggregation of Aβ peptide, specifically K114, (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene, which was initially developed as a potential positron emission tomography (PET) ligand for the in vivo detection of amyloid plaques. Systemic administration of K114 has been shown in the AD/transgenic (Tg) mouse model to be capable of crossing the blood-brain barrier (BBB) and be colocalized with amyloid plaques. In this study we determined whether K114 has the potential to inhibit Aβ aggregation in vitro in AD/Tg mice and also tested, in vivo, whether chronic daily orally administered K114 has any therapeutic potential as evidenced by inhibition or reduction of the deposits of amyloid aggregates in the brains of AD/Tg mice. Our results demonstrated that K114 strongly blocked, in vitro, the aggregation of Aβ peptide in the amyloid plaques of AD/Tg mouse brain. Systemic treatment with K114 was also effective in significantly reducing the deposits of amyloid plaques in the brains of living transgenic AD mice. Additionally, K114 significantly inhibited the typically observed plaque associated astrocytic activation, as revealed by GFAP immunohistochemistry, suggesting possible anti-inflammatory properties.

Original languageEnglish
Pages (from-to)299-308
Number of pages10
JournalCurrent Alzheimer Research
Volume11
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Amyloid Plaques
Transgenic Mice
Alzheimer Disease
Inflammation
Peptides
Brain
Ligands
tau Proteins
Neurofibrillary Tangles
Amyloid beta-Peptides
Brain Diseases
In Vitro Techniques
Blood-Brain Barrier
Neurodegenerative Diseases
Positron-Emission Tomography
Anti-Inflammatory Agents
Immunohistochemistry
Therapeutics

Keywords

  • Aggregation
  • Alzheimer's disease
  • Amyloid plaques
  • Amyloid-β
  • Astrocytes
  • K114

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice. / Zhang, Yi Hong; Mann, Dushyant; Raymick, James; Sarkar, Sumit; Paule, Merle G.; Lahiri, Debomoy; Dumas, Melanie; Bell-Cohen, Ashlee; Schmued, Larry C.

In: Current Alzheimer Research, Vol. 11, No. 3, 2014, p. 299-308.

Research output: Contribution to journalArticle

Zhang, YH, Mann, D, Raymick, J, Sarkar, S, Paule, MG, Lahiri, D, Dumas, M, Bell-Cohen, A & Schmued, LC 2014, 'K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice', Current Alzheimer Research, vol. 11, no. 3, pp. 299-308. https://doi.org/10.2174/1567205011666140220125324
Zhang, Yi Hong ; Mann, Dushyant ; Raymick, James ; Sarkar, Sumit ; Paule, Merle G. ; Lahiri, Debomoy ; Dumas, Melanie ; Bell-Cohen, Ashlee ; Schmued, Larry C. / K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice. In: Current Alzheimer Research. 2014 ; Vol. 11, No. 3. pp. 299-308.
@article{bd49abeaf4e4479393aa9736685b953c,
title = "K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice",
abstract = "Alzheimer's disease (AD) is the most common age related human neurodegenerative disorder. The major histopathological characteristics of the AD brain are extracellular amyloid-beta (Aβ) peptide loaded plaques and intraneuronal neurofibrillary tangles made of phosphorylated tau proteins. Amyloid plaques consist primarily of aggregated Aβ1-42 and Aβ1-40 peptides. The aim of our current study was to test novel ligands/agents with the potential to disrupt or inhibit the aggregation of Aβ peptide, specifically K114, (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene, which was initially developed as a potential positron emission tomography (PET) ligand for the in vivo detection of amyloid plaques. Systemic administration of K114 has been shown in the AD/transgenic (Tg) mouse model to be capable of crossing the blood-brain barrier (BBB) and be colocalized with amyloid plaques. In this study we determined whether K114 has the potential to inhibit Aβ aggregation in vitro in AD/Tg mice and also tested, in vivo, whether chronic daily orally administered K114 has any therapeutic potential as evidenced by inhibition or reduction of the deposits of amyloid aggregates in the brains of AD/Tg mice. Our results demonstrated that K114 strongly blocked, in vitro, the aggregation of Aβ peptide in the amyloid plaques of AD/Tg mouse brain. Systemic treatment with K114 was also effective in significantly reducing the deposits of amyloid plaques in the brains of living transgenic AD mice. Additionally, K114 significantly inhibited the typically observed plaque associated astrocytic activation, as revealed by GFAP immunohistochemistry, suggesting possible anti-inflammatory properties.",
keywords = "Aggregation, Alzheimer's disease, Amyloid plaques, Amyloid-β, Astrocytes, K114",
author = "Zhang, {Yi Hong} and Dushyant Mann and James Raymick and Sumit Sarkar and Paule, {Merle G.} and Debomoy Lahiri and Melanie Dumas and Ashlee Bell-Cohen and Schmued, {Larry C.}",
year = "2014",
doi = "10.2174/1567205011666140220125324",
language = "English",
volume = "11",
pages = "299--308",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice

AU - Zhang, Yi Hong

AU - Mann, Dushyant

AU - Raymick, James

AU - Sarkar, Sumit

AU - Paule, Merle G.

AU - Lahiri, Debomoy

AU - Dumas, Melanie

AU - Bell-Cohen, Ashlee

AU - Schmued, Larry C.

PY - 2014

Y1 - 2014

N2 - Alzheimer's disease (AD) is the most common age related human neurodegenerative disorder. The major histopathological characteristics of the AD brain are extracellular amyloid-beta (Aβ) peptide loaded plaques and intraneuronal neurofibrillary tangles made of phosphorylated tau proteins. Amyloid plaques consist primarily of aggregated Aβ1-42 and Aβ1-40 peptides. The aim of our current study was to test novel ligands/agents with the potential to disrupt or inhibit the aggregation of Aβ peptide, specifically K114, (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene, which was initially developed as a potential positron emission tomography (PET) ligand for the in vivo detection of amyloid plaques. Systemic administration of K114 has been shown in the AD/transgenic (Tg) mouse model to be capable of crossing the blood-brain barrier (BBB) and be colocalized with amyloid plaques. In this study we determined whether K114 has the potential to inhibit Aβ aggregation in vitro in AD/Tg mice and also tested, in vivo, whether chronic daily orally administered K114 has any therapeutic potential as evidenced by inhibition or reduction of the deposits of amyloid aggregates in the brains of AD/Tg mice. Our results demonstrated that K114 strongly blocked, in vitro, the aggregation of Aβ peptide in the amyloid plaques of AD/Tg mouse brain. Systemic treatment with K114 was also effective in significantly reducing the deposits of amyloid plaques in the brains of living transgenic AD mice. Additionally, K114 significantly inhibited the typically observed plaque associated astrocytic activation, as revealed by GFAP immunohistochemistry, suggesting possible anti-inflammatory properties.

AB - Alzheimer's disease (AD) is the most common age related human neurodegenerative disorder. The major histopathological characteristics of the AD brain are extracellular amyloid-beta (Aβ) peptide loaded plaques and intraneuronal neurofibrillary tangles made of phosphorylated tau proteins. Amyloid plaques consist primarily of aggregated Aβ1-42 and Aβ1-40 peptides. The aim of our current study was to test novel ligands/agents with the potential to disrupt or inhibit the aggregation of Aβ peptide, specifically K114, (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene, which was initially developed as a potential positron emission tomography (PET) ligand for the in vivo detection of amyloid plaques. Systemic administration of K114 has been shown in the AD/transgenic (Tg) mouse model to be capable of crossing the blood-brain barrier (BBB) and be colocalized with amyloid plaques. In this study we determined whether K114 has the potential to inhibit Aβ aggregation in vitro in AD/Tg mice and also tested, in vivo, whether chronic daily orally administered K114 has any therapeutic potential as evidenced by inhibition or reduction of the deposits of amyloid aggregates in the brains of AD/Tg mice. Our results demonstrated that K114 strongly blocked, in vitro, the aggregation of Aβ peptide in the amyloid plaques of AD/Tg mouse brain. Systemic treatment with K114 was also effective in significantly reducing the deposits of amyloid plaques in the brains of living transgenic AD mice. Additionally, K114 significantly inhibited the typically observed plaque associated astrocytic activation, as revealed by GFAP immunohistochemistry, suggesting possible anti-inflammatory properties.

KW - Aggregation

KW - Alzheimer's disease

KW - Amyloid plaques

KW - Amyloid-β

KW - Astrocytes

KW - K114

UR - http://www.scopus.com/inward/record.url?scp=84897458006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897458006&partnerID=8YFLogxK

U2 - 10.2174/1567205011666140220125324

DO - 10.2174/1567205011666140220125324

M3 - Article

VL - 11

SP - 299

EP - 308

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 3

ER -